Licensed Products. In addition to the Milestone Payments and the Annual Net Sales payments set forth in Section 6.3 above, during the Royalty Term, [[Savara:Organization]] shall pay to [[Grifols:Organization]] royalties based on the Net Sales by [[Savara:Organization]] or its sublicensees of all Licensed Products in the Territory. The royalty rate shall begin on January 1 of each calendar year and shall be in the following percentages:

Licensed Products. Effective as of the Option Effective Date and subject to the terms and conditions of this Agreement, [[Agenus:Organization]] hereby grants to Gilead a royalty-bearing, exclusive, transferrable (solely pursuant to [Section 16.4]), and sublicenseable (through multiple tiers) license, under the [[Agenus:Organization]] IP, to Develop, Manufacture, and Commercialize the Licensed Products in the Field in the Territory.

Solely with respect to the United States, if the manufacture, use or sale of a Licensed Product in the United States is not covered by a Valid Claim, then the royalty rates above shall be decreased by ​ until such time, if any, as such Licensed Product is covered by a Valid Claim.

Autologous Licensed Products; Allogeneic Licensed Products. During the applicable Royalty Term, Roche shall pay Poseida, in accordance with [Article 9], on a per- Royalty Eligible Autologous Licensed Product or per-Royalty Eligible Allogeneic Licensed Product, as applicable, and country-by-country basis, and subject to [Sections 8.9.2(b) and 8.9.4]4], a non-creditable, non-refundable, a royalty of ​ on worldwide Annual Net Sales of such Royalty Eligible Autologous Licensed Product or Royalty Eligible Allogeneic Licensed Product, as applicable. On a country-by-country basis, an Autologous Licensed Product is a “Royalty Eligible Autologous Licensed Product” or an Allogeneic Licensed Product is a “Royalty Eligible Allogeneic Licensed Product”, as applicable, if either # ​ or # ​.

Licensed Core Products. With respect to any Licensed Core Products, the conditions set forth in [clause (b) of Section 2.2] and [clause (b) of Section 2.3], and the license granted to Baylor under Section 2.6(a) shall continue with full force and effect as though no Change of Control had occurred.

Licensed Products Packaging. All Licensed Products produced under this Agreement shall be packaged in packaging which meets all requirements of Applicable Law and has been approved by Licensor pursuant to Section 6.3 (the “Packaging”). Licensee is responsible for ensuring, and further represents, warrants and covenants, that all Licensed Products are and shall be packaged in the Packaging.

Autologous Licensed Products. Roche shall pay Poseida each non- creditable, non-refundable, milestone payment set forth in the following table, in accordance with [Section 9.1.1], following the first achievement of the corresponding milestone event by an Autologous Licensed Product that is ​:

Allogeneic Licensed Products. Roche shall pay Poseida each milestone payment set forth in the following table, in accordance with [Section 9.1.1], following the first achievement of the corresponding milestone event by an Allogeneic Licensed Product that is ​:

Autologous Licensed Products. Roche shall pay Poseida each non- creditable, non-refundable milestone payment set forth in the following table, in accordance with [Section 9.1.2], following the first achievement of the corresponding milestone event for Autologous Licensed Products that are ​:

Allogeneic Licensed Products. Roche shall pay Poseida each non- creditable, non-refundable milestone payment set forth in the following table, in accordance with [Section 9.1.2], following the first achievement of the corresponding milestone event for Allogeneic Licensed Products that are ​: